Press and media
Press releases
More regular updates and key information, updates and news can be found through our tweets
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
CellCentric strengthens leadership team
Latest tweets from @CellCentric
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN